Etiology of pyoderma gangrenosum is unknown, but it can be associated with various systemic illnesses, including inflammatory bowel disease, rheumatoid arthritis, cancers, and hematologic disorders (eg, monoclonal gammopathy of undetermined significance, myelodysplastic syndrome, polycythemia vera). It is thought to be mediated by an abnormal immune response. Most patients are age 25 to 55. It can manifest in various subtypes.
Most often, pyoderma gangrenosum begins as an inflamed erythematous papule, pustule, or nodule. The lesion, which may resemble a furuncle or an arthropod bite at this stage, then ulcerates and expands rapidly, developing a swollen necrotic base and a raised dusky to violaceous border. An undermined border (ie, loss of underlying support tissue at the border) is common, if not pathognomonic. Systemic symptoms such as fever and malaise are common. The ulcers can coalesce to form larger ulcers, often with cribriform or sieve-like scarring.
Symptoms and signs can vary with the subtype.
Pyoderma gangrenosum can also develop at other sites, such as around a stoma in patients who have inflammatory bowel disease (peristomal pyoderma gangrenosum), on the genitals (genital pyoderma gangrenosum), or in sites other than the skin, such as the bones, cornea, central nervous system, heart, intestine, liver, lungs, or muscle (extracutaneous pyoderma gangrenosum).
Diagnosis of pyoderma gangrenosum is clinical and is a diagnosis of exclusion after other causes of ulceration have been ruled out. Expansion of ulceration after surgical debridement strongly suggests pyoderma gangrenosum. Biopsies of lesions are not often diagnostic but may be supportive; 40% of biopsies from a leading edge show vasculitis with neutrophils and fibrin in superficial vessels.
Patients who have bullous (atypical) pyoderma gangrenosum should be monitored with periodic clinical assessment and complete blood count for development of a hematologic disorder.
Wound healing can be promoted with moisture-retaining occlusive dressings for less exudative plaques and absorptive dressings for highly exudative plaques. Biologic and other specialized dressings may be needed in refractory cases. Wet-to-dry dressings should be avoided. Topical therapy with high-potency corticosteroids or tacrolimus can help with superficial and early lesions.
For more severe manifestations, prednisone 60 to 80 mg orally once a day is a common first-line therapy. TNF-alpha inhibitors (eg, infliximab, adalimumab, etanercept) are effective, particularly in patients who have inflammatory bowel disease. Cyclosporine 3 mg/kg orally once a day is also quite effective, particularly in rapidly progressive disease. Dapsone, azathioprine, cyclophosphamide, methotrexate, clofazimine, thalidomide, and mycophenolate mofetil have also been used successfully. Antimicrobials such as minocycline have also been used for vegetative (superficial) pyoderma gangrenosum.
Surgical treatments are avoided because of the risk of wound extension (1).
Pyoderma gangrenosum is often associated with a systemic disorder and is probably immune-mediated.
There are several subtypes; the ulcerative subtype (ie, necrotic base and raised violaceous border with undermined edge on a lower extremity, buttock, or perineum) is most common.
Diagnose pyoderma gangrenosum clinically.
Optimize wound care and avoid surgical debridement.
Use potent topical corticosteroids or tacrolimus to treat early lesions and use systemic corticosteroids, tumor necrosis factor (TNF)-alpha inhibitors, or other anti-inflammatories or immunosuppressants to treat more severe manifestations.